

22 July 2020


## ASX ANNOUNCEMENT

### Scripps Collaboration Preps SOZO for Heart Failure Launch

**Brisbane, Australia** – ImpediMed Limited (ASX:IPD), a medical software technology company that non-invasively measures, monitors and manages fluid status and tissue composition using bioimpedance spectroscopy (BIS), today announced it is launching its fluid analysis for heart failure software for the SOZO® Digital Health Platform. The launch follows an intensive round of review and improvements in collaboration with Dr. Tom Heywood and Dr. Andrew Accardi at Scripps Health in San Diego, California USA. The updates improve usability and data visualisation for cardiologists to implement SOZO as an objective measure of fluid volume for their heart failure patients.

“Traditionally clinicians have poor tools for determining the degree of congestion in heart failure, which leads to costly hospital admissions for heart failure patients and can result in readmissions after discharge,” said Dr. Tom Heywood, Heart Failure Cardiologist and principal investigator of ImpediMed’s heart failure home study. “Our initial clinical trial experience with SOZO has been very positive and we look forward to the opportunity to use SOZO in daily practice,” added Dr. Andrew Accardi, Emergency Medicine physician and co-investigator of the study.

The SOZO fluid analysis for heart failure is a novel tool for assessing fluid overload in heart failure. It utilises ImpediMed’s HF-Dex™ heart failure index which is a measure of extracellular fluid as a percent of total body water. The recent improvements incorporated colour-coded HF-Dex reference ranges and additional colour-coded graphs to show extracellular, intracellular, and total body fluid volumes as well as weight.



The HF-Dex reference ranges were derived from an analysis of heart failure patients from ImpediMed's heart failure home study and research performed on healthy subjects. The heart failure home study is an observational study that tracks recently hospitalised heart failure patients with daily SOZO tests at home. The analysis, which is in the process of being published, yielded BIS-derived reference ranges for normal fluid volumes, elevated fluid volumes, and fluid overload, which is defined as HF-Dex greater than 51%. Data from this study, combined with individual patient case reports illustrates the benefits of SOZO in heart failure patients:

- Differentiating between fluid and tissue-related weight changes
- Tracking response to medication changes
- A marker for readmission when HF-Dex is higher than 51%.

"Through our collaborations with leading physicians such as Dr. Heywood and Dr. Accardi from Scripps, we are building a comprehensive solution for patient management," said Richard Carreon, CEO and Managing Director of ImpediMed. "With our software-based approach to product improvements, we can respond quickly and act on critical feedback, which will help to ensure the commercial launch of our heart failure application in the current financial year."

"We thank Dr. Heywood and Dr. Accardi for their leadership and insights, which will contribute greatly to improved patient care," he continued.

**Approved for release by the Managing Director and CEO, Mr Richard Carreon.**

## **Contact Details**

### **Investor relations Contact:**

Mike Bassett, ImpediMed  
T: +61 407 431 432  
E: [mbassett@impedimed.com](mailto:mbassett@impedimed.com)

### **Media Contact:**

Kyahn Williamson, WE Buchan  
T: +61 3 9866 4722  
E: [kwilliamson@weworldwide.com](mailto:kwilliamson@weworldwide.com)

## **About ImpediMed**

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical software technology company that non-invasively measures, monitors and manages fluid status and tissue composition using bioimpedance spectroscopy (BIS).

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO® for multiple indications including heart failure, protein calorie malnutrition and lymphoedema, sold in select markets globally.

For more information, visit [www.impedimed.com](http://www.impedimed.com).

## **About SOZO Digital Health Platform**

SOZO, the world's most advanced, noninvasive bioimpedance spectroscopy (BIS) device, delivers a precise snapshot of fluid status and tissue composition in less than 30 seconds. Using ImpediMed's BIS technology, SOZO measures 256 unique data points over a wide spectrum of frequencies from 3 kHz to 1000 kHz. Results are available immediately online for easy data access and sharing across an entire healthcare system. The FDA-cleared, CE-marked and ARTG-listed digital health platform aids in the early detection of secondary lymphedema, provides fluid status for patients living with heart failure, and can be used to monitor and maintain overall health – all on a single device.

For more information, visit: <https://www.impedimed.com/products/sozo/>

**About SOZO Fluid Analysis for Heart Failure**

The SOZO fluid analysis for heart failure provides an objective measure of fluid overload in heart failure patients. It utilises ImpediMed's HF-Dex™ heart failure index which is a measure of extracellular fluid as a percent of total body water. HF-Dex is presented on BIS-derived reference ranges which indicate normal fluid volumes, elevated fluid volumes, and fluid overload, which is defined as HF-Dex greater than 51%. When used as part of a clinical assessment of heart failure patients, SOZO helps differentiate between fluid and tissue-related weight changes, track response to medication changes, and provides a marker for readmission when HF-Dex is higher than 51%.

For more information, visit: <https://www.impedimed.com/healthcare/heart-failure/>

**Forward-Looking Statements**

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to expand sales and market acceptance in the US and Australia including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialise new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. ImpediMed does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. ImpediMed may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.